Shared-decision Making in AD: Incorporating the Minimal Disease Activity Concept With Vimal Hasmukh Prajapati, MD, FRCPC April 7, 2025
FDA Approves New Nonsteroidal Topical for AD: All About Tapinarof Cream, 1% (Vtama, Organon) December 16, 2024
Tapinarof Cream 1% (Vtama, Organon) Approved in AD: Organon’s Phil Brown, MD, JD, Discusses the New Indication December 16, 2024
U.S. FDA Approves Nemolizumab (Nemluvio, Galderma) for Patients with Moderate to Severe AD December 14, 2024
